

ASX Announcement

Melbourne, Thursday 25 January 2007

43% Increase In First Half Sales


CogState Ltd (ASX:CGS), a leader in the development and marketing of computerised tests for cognition (brain function), today announced a 43% increase in its sales revenue for the first half of financial year 2007.

Sales revenue for the six months ended 31 December 2006 was \$1.19 million, compared to \$0.83 million for the previous corresponding period.

The quarter ended 31 December 2006 was CogState's most successful sales quarter ever. Sales revenue was \$0.82m for the three months; a 124% increase on the previous quarter (quarter ended September 2006) and a 20% increase on the previous highest quarterly sales revenue (quarter ended June 2006).

Mr Brad O'Connor, Chief Executive Officer of CogState said: "As the global market for computerised cognitive testing gets bigger, we are looking to increase our share of that market. Many of the major pharmaceutical companies, such as Pfizer, GlaxoSmithKline and Merck, already use our products in their clinical trials, which is laying a good foundation for continued sales growth into the future."

The graph below shows the quarterly sales revenue figures for the previous three years by quarter:





CogState Ltd
ABN 80 090 975 723

Level 7
21 Victoria Street
Melbourne Vic 3000
Australia

About CogState

CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.

Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, GlaxoSmithKline, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group) and Organon USA. CogState is currently expanding its existing activities in the US clinical trial markets.

For additional information:

Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com

Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au